Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Guadecitabine in Advanced Urothelial Cancer
NCT03179943Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in urothelial carcinoma (UC), sponsored by Fox Chase Cancer Center. Primary endpoints: Maximum Tolerated Dose of Guadecitabine in combination of Atezolizumab and Objective Response Rate at 2 years. Started Nov 2017; status: active, not recruiting.
02
Drugs
guadecitabine
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03179943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179943.